Journal
BLOOD
Volume 118, Issue 19, Pages 5084-5095Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2011-07-365817
Keywords
-
Categories
Funding
- National Institutes of Health [R01 CA72669, HL56067, AI34495]
- Leukemia and Lymphoma Translational Research [R6029-07]
- [P01 CA142106]
- [AI056299]
- [CA067493]
Ask authors/readers for more resources
The microenviroment of acute myelogenous leukemia (AML) is suppressive for immune effector cells. Regulatory T cells (Tregs) have been recognized as a contributor factor and may be recruited and exploited by leukemic cells to evade immunesurveillance. Studies have shown that the frequencies of marrow and blood Tregs are greater in patients with AML than in control patients. Although increased Tregs have been associated with a decreased risk of GVHD after allogeneic HCT and hence may impede the graft-versus-tumor effect, recent findings indicate that that this may not be the case. Because there is a need to improve outcomes of standard treatment (chemotherapy with or without allogeneic HCT) in AML, targeting Tregs present an outstanding opportunity inAML because discoveries may apply throughout its treatment. Here, we review data on the roles of Tregs in mediating immune system-AML interactions. We focused on in vitro, animal, and observational human studies of Tregs inAML biology, development, prognosis, and therapy in different settings (eg, vaccination and HCT). Manipulation of Tregs or other types of immunomodulation may become a part of AML treatment in the future. (Blood. 2011;118(19):5084-5095)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available